An interventional study of Fluid restriction strategy and Thirst-driven, liberal fluid intake in Acute Heart Failure (AHF), sponsored by Gødstrup Hospital. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.
Sponsored by Gødstrup Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 242 studies in Heart Failure with a site in Denmark — 52 open to participants now, 60 under way, 9 of them phase 3. Heart Failure · Denmark.
Among the 242 studies in Heart Failure with a site in Denmark, this one is the 78th largest by planned enrollment of the 187 interventional ones that give a count, is one of 12 that started in 2026, is one of 89 with no phase, reaches primary completion later than 42 of the 59 other live ones, and was the 232nd registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →52 of the 242 studies in Heart Failure with a site in Denmark are open now. Recruiting first, the newest first:
Odense University Hospital · Sites in Denmark
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark, Finland, Norway and 1 more country
Ages 18–99
University of Aarhus · Sites in Denmark
Ages 18+
Novo Nordisk A/S · Sites in Denmark, United States, Argentina and 24 more countries
Ages 18+
Aarhus University Hospital · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
242 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 39 · Phase 3 43 · Phase 4 15
First in 1983; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 420 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 197 across the 187 interventional studies, 213 across the 54 observational. Of the 159 that completed or were terminated, 55 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
94 of 242 have an industry lead sponsor. The 10 most frequent:
Gødstrup Hospital is the lead sponsor of 24 studies on the registry; 14 are open to participants now.
Gødstrup Hospital has 2 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
6 of the studies in Heart Failure with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04709900Copenhagen University Hospital, RigshospitaletCT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes | 2026-12 |
| NCT05104658Center for Clinical Research and PreventionHeart Rehabilitation for All | 2026-12-31 |
| NCT05063955Aarhus University HospitalMechanism of Sarcopenia in Heart Failure | 2026-12-31 |
| NCT05276219Copenhagen University Hospital, RigshospitaletDECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure | 2027-05-01 |
| NCT05834803University of AarhusEffects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients. | 2027-06-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 242 studies in Heart Failure with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this clinical trial is to learn whether a thirst-driven, liberal fluid-intake strategy is comparable to a fluid-restriction strategy in patients hospitalized for acute decompensated heart failure (ADHF). The study will also assess the safety of the intervention and its effects on thirst and quality of life.
Patients hospitalized with ADHF will be asked to follow either a thirst-driven fluid-intake strategy or a fluid-restriction strategy during their hospital stay and for one month after discharge.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Hospitalized for ADHF as the primary diagnosis, meeting both of the following:
i. ≥2 physical signs (edema, ascites, pulmonary rales/crackles, increased JVP, S3 gallop, rapid weight gain due to fluid retention), OR ii. ≥1 physical sign AND ≥1 laboratory finding indicative of ADHF (BNP >500 ng/L or NT-proBNP >2000 ng/L if sinus rhythm, or BNP >750 ng/L or NT-proBNP >3000 ng/L if atrial fibrillation, radiological/ultrasound evidence of pulmonary congestion, echocardiographic sign [VCI >2.1 cm, LVOT VTI \<15 cm, E/e' >14, D-dominant pulmonary venous inflow pattern], or invasive evidence [CVP >12 mmHg, PCWP >18 mmHg, CI \<2.2 L/min/m2]).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Thirst-driven, liberal fluid intake
Behavioral: Fluid restriction strategy
Fluid restriction of 1.5 L/day
Liberal fluid intake driven by thirst without restrictions
Time to clinical stability
Time from randomization to clinical stability. Clinical stability is defined as: 1. Off IV loop diuretics for ≥ 24 hours without need for reinitiation of IV diuretics. 2. No evidence of pulmonary congestion, defined as both: i) No new or worsening dyspnea at rest compared with status at admission ii) Clear lung auscultation or clinically improved, or normal lung and/or vena cava ultrasound without evidence of congestion. 3. No new or worsening peripheral edema compared with status at admission.
Time frame: From enrollment to 1 month follow-up
Thirst Distress
Thirst Distress Scale for patients with Heart Failure (TDS-HF). Scores range from 8 to 40. Higher scores indicate greater thirst-related distress
Time frame: From enrollment to 1 month follow up
Patient-perceived Quality of Life
Kansas City Cardiomyopathy Questionnaire (KCCQ). Scores range from 0 to 100, with higher scores indicating better health status.
Time frame: From enrollment to 1 month follow up
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
Number of occurrences during hospitalization of clinical worsening (escalation of HF therapy, such as vasopressor/inotrope initiation, ICU transfer, dialysis, reinitiation of IV diuretics), electrolyte disturbances, worsening renal function, or in-hospital death, and similarly after one month including HF hospitalization
Time frame: From enrollment to 1 month follow up
Plan to share: Undecided — Due to regulations by Region Committees on Health Research Ethics
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for May 2029, 36 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 36 months is above that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gødstrup Hospital